ReviewHNO2025
[Acute rhinosinusitis in the adult patient].
Review in HNO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute rhinosinusitis (ARS) is usually primarily a viral disease. During the course of the disease, bacteria can be detected by culture in about half of the cases. With a focus on the resulting treatment options, ARS is classified as acute viral RS (AVRS; duration < 10 days), acute post-viral RS (APVRS; worsening after approximately 5 days and/or duration > 10 days), and acute bacterial RS (ABRS; at least three of the following five criteria: fever > 38 °C, biphasic disease course, unilateral symptoms, severe pain, and elevated C‑reactive protein [CRP]). AVRS can be treated with zinc, decongestants, nonsteroidal anti-inflammatory drugs (NSAIDs), and phytotherapeutics. Intranasal steroids (INS) are additionally helpful for APVRS and antibiotics only for ABRS. The substance of first choice is amoxicillin; the potential benefit should be weighed against possible side effects and development of resistance in each individual case.
Indexed as
Identifiers
40493235What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.